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Abstract
Background: Rating scale items in a 6-week clinical trial of olanzapine versus placebo augmentation in patients
with mixed bipolar disorder partially nonresponsive to ≥14 days of divalproex monotherapy were analyzed to
characterize symptom patterns that could predict remission. At baseline, the two treatment groups were similar.
Findings: Factor analysis with Varimax rotation was performed post hoc on baseline items of the 21-Item Hamilton
Depression Rating Scale (HDRS-21) and Young Mania Rating Scale (YMRS). Backwards-elimination logistic regression
ascertained factors predictive of protocol-defined endpoint remission (HDRS-21 score ≤ 8 and YMRS score ≤ 12)
with subsequent determination of optimally predictive factor score cutoffs.
Factors for Psychomotor activity (YMRS items for elevated mood, increased motor activity, and increased speech
and HDRS-21 agitation item) and Guilt/Suicidality (HDRS-21 items for guilt and suicidality) significantly predicted
endpoint remission in the divalproex+olanzapine group. No factor predicted remission in the divalproex+placebo
group. Patients in the divalproex+olanzapine group with high pre-augmentation psychomotor activity (scores ≥10)
were more likely to remit compared to those with lower psychomotor activity (odds ratio [OR] = 3.09, 95% confi-
dence interval [CI] = 1.22-7.79), and patients with marginally high Guilt/Suicidality (scores ≥2) were less likely to
remit than those with lower scores (OR = 0.37, 95% CI = 0.13-1.03). Remission rates for divalproex+placebo vs.
divalproex+olanzapine patients with high psychomotor activity scores were 22% vs. 45% (p = 0.08) and 33% vs.
48% (p = 0.29) for patients with low Guilt/Suicidality scores.
Conclusions: Patients who were partially nonresponsive to divalproex treatment with remaining high vs. low
psychomotor activity levels or minimal vs. greater guilt/suicidality symptoms were more likely to remit with
olanzapine augmentation.
Trial Registration: ClinicalTrials.gov; http://clinicaltrials.gov/ct2/show/NCT00402324?term=NCT00402324&rank=1,
Identifier: NCT00402324
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Background
Variable pharmacologic treatment response has led to
analyses of associations with previous clinical course
[1-4] and baseline clinical characteristics [1,3,5,6] to
develop tailored therapies. A post hoc factor analysis of
baseline components from the 21-item Hamilton
Depression Rating Scale (HDRS-21 [7]) and the Young
Mania Rating Scale (YMRS) [8] in bipolar I disorder
patients with a current mixed episode characterized spe-
cific baseline mood symptoms which potentially pre-
dicted remission with treatment augmentation. Data
were from a 6-week, double-blind, placebo-controlled
trial, of olanzapine (OLZ) augmentation in patients with
inadequate response to divalproex (DPX). The primary
efficacy endpoint for the original clinical trial was a
change in YMRS and HDRS-21 from baseline across 6
weeks by therapy. The primary study was reviewed and
approved by the institutional review board at each site,
and was conducted in accordance with the International
Conference on Harmonisation Good Clinical Practice
guidelines. Verbal and written informed consent was
obtained from all subjects prior to participation. The
study, which demonstrated a statistically significant dif-
ference between overall treatment groups in improve-
ment over 6 weeks (in both YMRS and HDRS-21
scores), primary endpoints for the original clinical trial,
was not adequately powered to show a difference in
treatment arms for dual remission rate (31% vs. 26%,
p = .437 for OLZ augmentation vs. continued DPX
monotherapy) [9]. Part of the rationale for performing
the present analysis was to determine whether baseline
symptoms effectively determined sub-groups of patients
more likely to remit with olanzapine augmentation vs.
continued DPX monotherapy, given the low overall
remission rate.
Methods
Outpatients aged 18 to 60 years with bipolar I disorder,
current mixed episode (with or without psychotic fea-
tures), as defined by the Diagnostic and Statistical Man-
ual of Mental Disorders, 4th edition, (DSM-IV-TR;
diagnostic criteria 296.6x) were included. Those (n =
202) with inadequate response to ≥14 days of oral DPX
monotherapy (blood levels 75 to 125 μg/mL) were ran-
domly assigned to 6 weeks of placebo (PLA; [n = 101]) or
OLZ (mean modal daily dose 14.6 mg; n = 101]) augmen-
tation of DPX treatment. Inadequate response was
defined as a HDRS-21 score ≥16 and a YMRS score ≥16.
Clinical Global Impressions of Severity (CGI-S) for Bipo-
lar Illness scale data were also collected at baseline. Study
details are available elsewhere [9]. Briefly, baseline char-
acteristics of the two treatment groups at randomization
were similar in the DPX+PLA vs. DPX+OLZ study arms:
55% vs. 46% white, 29% vs. 38% African American, and
43% vs. 40% male with mean HDRS-21 scores of 21.9 vs.
22.5 and YMRS scores of 20.4 vs. 21.4 [9].
Factor analysis is a statistical technique that combines
individual variables varying in the same manner or
direction into representative summary factors. Factor
analysis permits a reduction in the dimensionality of the
original data and the identification of clinically-defined
patient subgroups. Factor analysis with Varimax rotation
was performed on HDRS-21 and YMRS items, obtained
prior to augmentation therapy [10]. Items with factor-
loading scores ≥0.4 were included in the one factor for
which they had the highest factor-loading score. Items
with a negative loading factor were reverse-scored. Only
factors with an eigenvalue > 1 were included in the ana-
lyses. Pearson correlation coefficients between these fac-
tors and CGI-S scores were determined at baseline.
Backwards-elimination logistic regression models were
run for DPX+OLZ and DPX+PLA separately for remis-
sion (HDRS-21 score ≤ 8 and YMRS score ≤ 12) at
6 weeks. Investigative site location (US vs. Puerto Rico)
and all factors derived from the factor analysis were
included in the initial model as potential predictors.
Variables were eliminated from the model at the 0.05
level of statistical significance.
Several potential cut-off scores (median, median ± 1,
2) for each factor that were significant in the logistic
regression models were investigated as predictors of
remission. T-tests of each of these potential cut-off
scores against remission were performed to find the fac-
tor cut-off score that best divided the remitters from the
non-remitters within that treatment group based on sta-
tistical significance. Sensitivity, specificity, positive pre-
dictive value (PPV), and negative predictive value (NPV)
were also determined. Logistic regression models were
performed using the categorical factor cut-off scores to
predict ultimate remission.
Analyses of the YMRS and HRDS-21 total scores over
time in sub-groups separated by initial factor cut-off
scores utilized the mixed model repeated measures
(MMRM) approach over 6 weeks. The models included
the fixed, categorical effects of factor cut-off score, visit,
baseline total score, investigative site, and visit-by-factor
cut-off interaction. The optimal within-subject covar-
iance matrix in each MMRM model was determined by
Bayesian Information Criterion after testing the follow-
ing options: unstructured, toeplitz, auto-regressive, and
compound-symmetric. SAS version 9.1.3 was used for
all analyses.
Remission rates for statistically significant factors in
patients sub-grouped by optimal cut-off factor scores
were compared between DPX+PLA and DPX+OLZ
groups by Fisher’s exact test.
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Results
Using principal factor analysis with Varimax rotation,
the 32 individual HDRS-21 and YMRS items were
reduced into 11 factors with eigenvalues > 1 as shown
in Table 1. These 11 factors explained 62% of the total
variance of the baseline HDRS-21 and YMRS item
scores. Eigenvalues did not drop substantially in value
across the sequence. Psychomotor activity (Factor 2),
Work impairment/somatization (Factor 4), Irritability
(Factor 5), Guilt/Suicidality (Factor 8), and Appearance/
Gastrointestinal symptoms (Factor 9) correlated signifi-
cantly with CGI-S (Table 1). Sleep disturbance (Factor
1) contributed significantly to the total scores from
HDRS-21 and YMRS items, but did not correlate signifi-
cantly with CGI-S. In a logistic regression model that
included these 11 factors at baseline and investigative
site as independent variables (and remission as the
dependent variable), only Psychomotor activity and
Guilt/Suicidality and investigative site were significant
predictors of remission in DPX+OLZ-treated patients
(Table 2). In the DPX-PLA treated patients, no factors
remained in the backwards elimination model at a 0.05
significance level.
Further analysis of Psychomotor activity and Guilt/
Suicidality factors revealed that baseline scores below
10 and 2, respectively, best separated patients who
achieved remission from those who did not (non-
remitters) with DPX+OLZ treatment. Logistic regres-
sion models using these categorical cut-offs showed
that those with Psychomotor activity (Factor 2) scores
≥10 were more likely to remit at endpoint (p = 0.02).
Those with Guilt/Suicidality (Factor 8) scores ≥2 were
less likely to remit at endpoint, although this relation-
ship did not quite reach significance (p = 0.06). The
sensitivity, specificity, PPV, and NPV of these cut-off
scores are shown in Table 2. As defined by these
scores, only 22% of patients without higher levels of
psychomotor activity and 26% of patients with even
modest levels of suicidality or guilt feelings remaining
after non-response to DPX treatment for at least 2
weeks remitted with OLZ augmentation.
In an MMRM model of changes in HDRS-21 and
YMRS total scores over time, those with Psychomotor
activity (Factor 2) scores ≥10 had significantly lower
totals on the HDRS-21 score from 2 weeks post-rando-
mization onwards (Figure 1A) and a significantly lower
YMRS score at 6 weeks, despite a significantly higher
YMRS score at baseline (Figure 1B). For Guilt/Suicidal-
ity (Factor 8), significant outcome differences were
observed only at approximately 5 weeks post-randomi-
zation for HDRS-21 and YMRS scores (Figures 1C and
1D).
Table 1 Factor Analysis [12] of Mania and Depression Symptoms
Factor No.
Name
Scale Items Mean Contribution To









YMRS 4 Sleep HDRS-21 4 Early Insomnia HDRS-21 5 Middle
Insomnia HDRS-21 6 Late Insomnia
13.90% 2.82 0.073 (0.301)
2. Psychomotor
activity
YMRS 1 Elevated Mood YMRS 2 Increased Psychomotor Activity
YMRS 6 Rapid Speech HDRS-21 9 Agitation
19.70% 2.53 0.253 (< .001)*




HDRS-21 7 Work and Activities HDRS-21 11 Somatic Anxiety HDRS-
21 13 General Somatic Symptoms
12.80% 2.10 0.293 (< .001)*
5. Irritability YMRS 5 Irritability YMRS 9 Disruptive Aggressive Behavior HDRS-21
1 Depressed Mood




HDRS-21 18b Diurnal Variation HDRS-21 19 Depersonalization and
Derealization HDRS-21 21 Obsessional and Compulsive Symptoms
2.90% 1.70 0.073 (0.303)
7. Sexuality YMRS 3 Sexual Interest HDRS-21 14 Genital Symptoms (reverse) 3.80% 1.48 -0.120 (0.089)
8. Guilt/Suicidality HDRS-21 2 Feelings of Guilt HDRS-21 3 Suicide 4.80% 1.38 0.256 (< .001)*
9. Appearance/GI YMRS 10 Appearance HDRS-21 12 Somatic Symptoms
(gastrointestinal) HDRS-21 16 Loss of Weight
3.10% 1.28 0.298 (< .001)*
10. Thought
disorder
YMRS 8 Content HDRS-21 20 Paranoid Symptoms 6.40% 1.25 0.012 (0.871)
11. Retardation/
Hypochondriasis
HDRS-21 8 Psychomotor Retardation (reverse) HDRS-21 15
Hypochondriasis
9.90% 1.08 0.118 (0.094)
* Statistically-significant (p < .05). GI: Gastrointestinal.
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Remission rates in the DPX+PLA vs. DPX+OLZ
groups were 21.9% vs. 44.7%, p = 0.08 for patients with
high psychomotor activity (score ≥10) and 33.3% vs.
47.8% (p = 0.29) for patients with low Guilt/Suicidality
(score < 2).
The categorical cut-off scores for Psychomotor activity
(Factor 2) and Guilt/Suicidality (Factor 8) were also
compared to the endpoint CGI-S score to evaluate their
association with a measure of remission not based on
YMRS or HDRS-21. Both of these categorical cut-offs in
the OLZ treatment group were associated with a nearly
half-point difference in the endpoint CGI-S scale though
these relationships did not reach statistical significance
(Psychomotor activity [Factor 2] < 10: mean CGI-S =
3.11 versus Psychomotor activity ≥10 mean CGI-S =
2.68, p = .08; Guilt/Suicidality (Factor 8) < 2, mean
CGI-S = 2.57 versus Guilt/Suicidality ≥2, mean CGI-S =
3.06, p = .05).
Discussion
We reduced 32 items of the HDRS-21 and YMRS at
baseline into 11 factors, of which 2 factors predicted
remission at 6 weeks following OLZ augmentation in
patients previously partially nonresponsive to DPX
monotherapy. Patients with greater baseline Psychomo-
tor activity (Factor 2 ≥10) were more likely to remit
with OLZ augmentation. These patients had lower final
YMRS and HDRS-21 scores after 6 weeks of OLZ
Figure 1 Total HDRS-21 (A and C) and YMRS (B and D) scores in sub-categorized patients. Patients were sub-categorized by cut-off scores
for baseline Psychomotor activity (Factor 2) and Guilt/suicidality (Factor 8) during olanzapine augmentation of divalproex-partially nonresponsive
patients. HDRS-21: 21-Item Hamilton Depression Rating Scale; YMRS: Young Mania Rating Scale.
Table 2 Details of Two Factors Predictive of Remission with Olanzapine Augmentation of Divalproex Partially
Nonresponsive Patients

























0.034 10 3.09 1.22 -
7.79
0.017 54.84 69.57 44.70 77.40
8. Guilt/Suicidality 0.61 0.39 -
0.94
0.025 2 0.37 0.13 -
1.03
0.056 35.48 82.61 47.80 74.01
The logistic regression models also included investigative site location (USA vs. Puerto Rico)
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augmentation despite significantly higher YMRS and
similar HDRS-21 scores at baseline. In contrast, patients
with even marginally high Guilt/Suicidality (Factor 8≥2)
were less likely to remit than those with lower levels of
symptomatology. Guilt/Suicidality (Factor 8) correlated
significantly with CGI-S scores despite a relatively low
contribution to overall HDRS-21 and YMRS total scores
(Table 1).
These findings along with relatively higher (although
statistically nonsignificant) remission rates for high psy-
chomotor activity and low Guilt/Suicidality groups with
OLZ augmentation vs. continued DPX treatment alone
suggest that these subgroups of patients may be better
candidates for OLZ augmentation after inadequate
response to DPX monotherapy. While Psychomotor
activity and Guilt/suicidality had only moderate PPVs
for remission (44.7% and 47.8%, respectively), in part
related to the low overall rate of remission, they both
had high NPVs (77.4% and 74.0%, respectively). Such
predictors could increase the overall remission rate with
OLZ augmentation through pre-treatment exclusion of
patients likely to be non-remitters.
It is difficult to compare factors from our analysis with
others in the literature because our population was
restricted to bipolar disorder patients experiencing a
mixed state. The factors we identified may be related to
the presence of substantial depressive and manic symp-
toms. Also, a greater number of eigenvalues resulted
from lack of at clear drop in eigenvalue magnitude
between factors that would have allowed the elimination
of factors associated with lower eigenvalues. Addition-
ally, the methodology of other analyses differs from
ours. One analysis developed a bivariate symptom rating
scale based on 2 factors identified from a principal fac-
tor analysis in a retrospective study in which patients
completed a symptom questionnaire based on their last
manic episode [11]. Another analysis that used principal
components factor analysis of HDRS-21 and YMRS
scores in a group of patients with bipolar disorder who
had experienced either mixed or manic states, yielded 5
factors corresponding to depression, dysphoria, hedon-
ism, psychosis, and activation [10].
Limitations
The likelihood of a type I error exists due to multiple
testing (individual item analysis). Results cannot be gen-
eralized to other settings for characterization of baseline
symptoms which predicted overall remission after OLZ
augmentation. Although YMRS and HDRS-21 scales
were used to define both predictors and outcomes, base-
line factors composed of YMRS and HDRS-21 individual
items defined predictors, and YMRS and HDRS-21
totals defined outcomes. YMRS and HDRS-21 measures
used for predictors vs. outcomes were at different time
points separated by up to six weeks. CGI-S scores also
showed similar differences in endpoint changes from
baseline when patients were sub-classified according to
the categorical factor cut-off scores. The percent contri-
bution of Factors 2 and 8 to total HDRS-21 and YMRS
scores at baseline were 20% and 5%, respectively (Table
1). Since the study was not adequately powered to show
a remission rate difference in treatment arms based
upon the above cut-off scores, comparison of remission
rates between treatments in high Psychomotor activity
and low Suicidality/Guilt subgroups is not fully conclu-
sive. While another limitation is that backwards elimina-
tion logistic regression is inferior to hypothesis-driven
modeling, this exploratory post-hoc analysis sought the
best predictive model using newly generated factors as
predictors. Because no specific hypotheses regarding the
factors were being tested, backwards elimination model
building was an appropriate strategy.
Conclusions
In this post hoc analysis of patients with bipolar disorder
mixed episodes, factor analysis suggested two groups of
HDRS-21 and YMRS items that predict remission in
patients receiving OLZ augmentation following an
inadequate response to DPX. Patients were more likely
to remit with OLZ augmentation vs. continued DPX
monotherapy if they scored lower on items related to
guilt and suicidality and higher on items related to psy-
chomotor activity.
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